Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
Johnson & Johnson (JNJ) reported Q3 2026 sales of $25.4B, up 5.9% YoY, but net earnings dropped 95.9% to $210M. Adjusted EPS was $2.59, down 7.5%. The company raised 2026 guidance, citing growth in MedTech and Innovative Medicine segments. Notable announcements include FDA approvals for IMAAVY and OTTAVA.
How this was made
The 30-second read
Why it matters
The Q3 earnings beat and raised guidance signal continued growth momentum, especially in Innovative Medicine, but the sharp GAAP EPS decline highlights ongoing cost pressures.
Market read
The earnings release and guidance lift are material for investors in JNJ and may influence sector sentiment.
What to watch
Potential legal liabilities and pending regulatory actions are not addressed in the release.
Background
Johnson & Johnson is a diversified health‑care conglomerate with pharmaceutical, medical device, and consumer segments.
Ticker impact
Johnson & Johnson disclosed Q3 2026 results and raised its 2026 operational sales and EPS guidance.
likely modest upside as investors price in higher future sales and earnings.
The company reported better‑than‑expected segment growth and lifted its full‑year operational sales and EPS outlook, which typically supports the share price.
Market effects
Positive guidance may lift broader healthcare and pharma stocks.
U.S. market may see a slight boost in large‑cap defensive sectors.
Limited to investors tracking major multinational health‑care firms.
Counterpoint
If the guidance raise is modest relative to expectations, the stock could be over‑bought and face a pull‑back.
Key entities
- ExecutiveJoaquin Duato
Chairman and CEO who commented on the results.
